| 10308610 |
Inhibitor compounds of phosphodiesterase type 10A |
Hervé Geneste, Michael Ochse, Jurgen Dinges, Clarissa Jakob |
2019-06-04 |
$590,682,000 |
| 10118926 |
Tricyclic quinoline and quinoxaline derivatives |
Hannes Fiepko KOOLMAN, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana-Lucia Relo +5 more |
2018-11-06 |
$227,839,000 |
| 9994568 |
Tricyclic quinoline and quinoxaline derivatives |
Hannes Fiepko KOOLMAN, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana-Lucia Relo +3 more |
2018-06-12 |
$512,591,000 |
| 9938269 |
Inhibitor compounds of phosphodiesterase type 10A |
Hervé Geneste, Michael Ochse, Berthold Behl, Loic Laplanche, Jurgen Dinges +2 more |
2018-04-10 |
$908,521,000 |
| 9856220 |
Inhibitor compounds of phosphodiesterase type 10A |
Hervé Geneste, Michael Ochse, Jurgen Dinges, Clarissa Jakob |
2018-01-02 |
$106,945,000 |
| 9790203 |
Inhibitor compounds of phosphodiesterase type 10A |
Hervé Geneste, Sean Colm Turner, Michael Ochse, Lawrence A. Black, Katja Jantos |
2017-10-17 |
$801,857,000 |
| 9657034 |
Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors |
Hervé Geneste, Michael Ochse, Sean Colm Turner, Berthold Behl, Loic Laplanche +4 more |
2017-05-23 |
|
| 9573950 |
Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators |
Gisela Backfisch, Margaretha Henrica Maria Bakker, Günter BLAICH, Wilfried Braje, Thomas ERHARD +9 more |
2017-02-21 |
$237,163,000 |
| 9540376 |
Hexahydrodiazepinoquinolines carrying a substituted alkyl radical |
Gisela Backfisch, Margaretha Henrica Maria Bakker, Günter BLAICH, Wilfried Braje, Thomas ERHARD +7 more |
2017-01-10 |
$139,904,000 |
| 9475808 |
Inhibitor compounds of phosphodiesterase type 10A |
Hervé Geneste, Michael Ochse, Berthold Behl, Loic Laplanche, Jurgen Dinges +1 more |
2016-10-25 |
$312,321,000 |
| 9464072 |
Treatment of central nervous system disorders |
R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Yixian Long, Jurgen Dinges +17 more |
2016-10-11 |
$171,188,000 |
| 9464085 |
Inhibitor compounds of phosphodiesterase type 10A |
Hervé Geneste, Michael Ochse, Clarissa Jakob |
2016-10-11 |
$171,188,000 |
| 9388180 |
Inhibitor compounds of phosphodiesterase type 10A |
Hervé Geneste, Michael Ochse, Clarissa Jakob, Maricel Torrent |
2016-07-12 |
$246,047,000 |
| 9388141 |
Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
Andreas Haupt, Jurgen Dinges, Liliane Unger, Karsten Wicke, Robert Van Waterschoot +1 more |
2016-07-12 |
$246,047,000 |
| 9388148 |
Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
Andreas Haupt, Jurgen Dinges, Liliane Unger, Karsten Wicke, Robert Van Waterschoot +1 more |
2016-07-12 |
$246,047,000 |
| 9376396 |
Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
Andreas Haupt, Jurgen Dinges, Liliane Unger, Karsten Wicke, Robert Van Waterschoot +2 more |
2016-06-28 |
$672,150,000 |
| 9273068 |
Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A |
Hervé Geneste, Michael Ochse, Sean Colm Turner, Berthold Behl, Loic Laplanche +3 more |
2016-03-01 |
$121,077,000 |
| 9200005 |
Inhibitor compounds of phosphodiesterase type 10A |
Katja Jantos, Michael Ochse, Hervé Geneste, Jayne Froggett, Clarissa Jakob +1 more |
2015-12-01 |
$100,538,000 |
| 9169253 |
Tricyclic quinoline and quinoxaline derivatives |
Hannes Fiepko KOOLMAN, Wilfried Braje, Helmut Mack, Andreas Haupt, Ana-Lucia Relo +3 more |
2015-10-27 |
$183,930,000 |
| 9163019 |
Inhibitor compounds of phosphodiesterase type 10A |
Hervé Geneste, Michael Ochse, Berthold Behl, Loic Laplanche, Jurgen Dinges +1 more |
2015-10-20 |
$87,093,000 |
| 8969552 |
Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
Andreas Haupt, Liliane Unger, Sean Colm Turner, Wilfried Braje, Roland Grandel +1 more |
2015-03-03 |
$62,912,000 |
| 8940902 |
Treatment of central nervous system disorders |
R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Yixian Chen, Jurgen Dinges +17 more |
2015-01-27 |
$84,369,000 |
| 8642642 |
Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor |
Roland Grandel, Wilfried Braje, Andreas Haupt, Sean Colm Turner, Udo Lange +2 more |
2014-02-04 |
|
| 8507469 |
Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
Thomas Schultz, Wilfried Braje, Sean Colm Turner, Andreas Haupt, Udo Lange +4 more |
2013-08-13 |
$26,628,000 |
| 8497273 |
Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor |
Roland Grandel, Wilfried Braje, Andreas Haupt, Sean Colm Turner, Udo Lange +1 more |
2013-07-30 |
$27,275,000 |
